Dapagliflozin: SGLT2 inhibitor antidiabetic agent

Drugs of the Future

Volumn 33, Issue 9, 2008, Pages 745-751

  Cole, P ^a   Vicente, M ^a   Castaner R ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BMS 512148; DAPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PHLORIZIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BACKACHE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIET RESTRICTION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG EXCRETION; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; FLANK PAIN; FOOD; FOOD DRUG INTERACTION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSURIA; HUMAN; HYPOGLYCEMIA; HYPOURICEMIA; KIDNEY TUBULE ABSORPTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTPRANDIAL STATE; POTASSIUM BLOOD LEVEL; QT INTERVAL; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

EID: 60749129226     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.09.1251351     Document Type: Article

References (40)

1. Ellsworth, B., Meng, W., Sher, P.M., Washburn, W.N., Wu, G. (Bristol-Myers Squibb Co.). C-Aryl glucoside SGLT2 inhibitors and method. EP 1506211, JP 2005531588, US 2002137903, US 6515117, WO 2003099836.
2. Crispino, G., Denzel, T.W., Deshpande, P.P. et al. (Bristol-Myers Squibb Co.). Methods of producing C-aryl glucoside SGLT2 inhibitors. CA 2512389, EP 1581543, JP 2006516257, US 2004138439, WO 2004063209.
3. Meng, W., Ellsworth, B.A., Nirschl, A.A. et al. Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008, 51(5): 1145-9.
4. American Diabetes Association Web site (accessed August 18, 2008).
5. Smyth, S., Heron, A. Diabetes and obesity: The twin epidemics. Nat Med 2006, 12(1): 75-80.
6. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008, 31(3): 596-615.
7. Narayan, K.M., Boyle, J.P., Geiss, L.S., Saaddine, J.B., Thompson, T.J. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006, 29(9): 2114-6.
8. Wild, S., Roglic, G., Green, A., Sicree, R., King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27(5): 1047-53.
9. King, H., Aubert, R.E., Herman, W.H. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998, 21(9): 1414-31.
10. Manuel, D.G., Schultz, S.F. Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada, 1996-1997. Diabetes Care 2004, 27(2): 407-14.
11. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2003, 26(1, Suppl.): S28-32.
12. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352(9131): 854-65.
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14): 977-86.
14. Wells, R.G., Pajor, A.M., Kanai, Y., Turk, E., Wright, E.M., Hediger, M.A. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol 1992, 263(3, Pt. 2): F459-65.
15. You, G., Lee, W.S., Barros, E.J. et al. Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 1995, 270(49): 29365-71.
16. Kanai, Y., Lee, W.S., You, G., Brown, D., Hediger, M.A. The human kidney low affinity Na+/glucose cotransporter SGLT2: Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994, 93(1): 397-404.
17. van den Heuvel, L.P., Assink, K., Willemsen, M., Monnens, L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002, 111(6): 544-7.
18. Oku, A., Ueta, K., Arakawa, K. et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999, 48(9): 1794-800.
19. Ehrenkranz, J.R.L., Lewis, N.G., Kahn, C.R., Roth, J. Phlorizin: A review. Diabetes Metab Res Rev 2005, 21(1): 31-8.
20. Meng, W., Washburn, W.N., Ellsworth, B.A. et al. Synthesis, SAR and evaluation of C-aryl glucosides as sodium-glucose cotransporter inhibitors for the treatment of type 2 diabetes. 234th ACS Natl Meet (Aug 19-23, Boston) 2007, Abst MEDI 57.
21. Washburn, W.N., Meng, W., Ellsworth, B.A. et al. Synthesis and characterization of dapagliflozin, a potent selective SGLT2 inhibitor for treatment of diabetes. 234th ACS Natl Meet (Aug 19-23, Boston) 2007, Abst MEDI 28.
22. Han, S., Hagan, D.L., Taylor, J.R. et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008, 57(6): 1723-9.
23. Li, L., Komoroski, B., Boulton, D., Brenner, E., Vachharajani, N., Kornhauser, D. Safety, pharmacokinetics, and pharmacodynamics of dapagliflozin (BMS-512148), a selective SGLT2 inhibitor, in an ascending, placebo-controlled, single-dose study in healthy adult subjects. 43rd Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 17-21, Amsterdam) 2007.
24. Brenner, E., Komoroski, B., Boulton, D., Li, L. Safety, pharmacokinetics, and pharmacodynamics of dapagliflozin (BMS-512148) in an ascending, placebo-controlled, multiple-dose study in healthy adult subjects. 43rd Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 17-21, Amsterdam) 2007.
25. Feng, Y., Zhang, L., Komoroski, B., Pfister, M. Population pharmacokinetic analysis of dapagliflozin in healthy and subjects with type 2 diabetes mellitus. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (April 2-5, Orlando) 2008] 2008, 83(Suppl. 1).
26. Komoroski, B., Brenner, E., Li, L., Vach-Harajani, N., Kornhauser, D. Dapagliflozin (BMS-512148), a selective inhibitor of the sodium-glucose uptake transporter 2 (SGLT2), reduces fasting serum glucose and glucose excursion in type 2 diabetes mellitus patients over 14 days. 67th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007.
27. Komoroski, B., Brenner, E., Li, L. Dapagliflozin (BMS-512148), a selective SGLT2 inhibitor, inhibits glucose resorption and reduces fasting glucose in patients with type 2 diabetes mellitus. 43rd Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 17-21, Amsterdam) 2007.
28. List, J.F., Woo, V.C., Morales Villegas, E., Tang, W., Fiedorek, F.T. Efficacy and safety of dapagliflozin in a dose-ranging monotherapy study of treatment-naive patients with type 2 diabetes. Diabetes [68th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 6-10, San Francisco) 2008] 2008, 57(Suppl. 1).
29. Pharmacokinetic drug interaction study with dapagliflozin and glimepiride in healtlhy subjects (NCT00562250). ClinicalTrials.gov Web site, September 30, 2008.
30. Renal impairment in type 2 diabetic subjects (NCT00554450). ClinicalTrials.gov Web site, September 30, 2008.
31. Glycemic efficacy and renal safety study of dapagliflozin in subjects with type 2 diabetes mellitus and moderate renal impairment (NCT00663260). ClinicalTrial.gov Web site, September 30, 2008.
32. Add-on to thiazolidinedione (TZD) failures (NCT00683878). ClinicalTrials.gov Web site, September 30, 2008.
33. A phase III study of BMS-512148 (dapagliflozin) in patients with type 2 diabetes who are not well controlled on metformin alone (NCT00528879). ClinicalTrials.gov Web site, September 30, 2008.
34. A phase III study of BMS-512148 (dapagliflozin) in patients with type 2 diabetes who are not well controlled with diet and exercise (NCT00528372). ClinicalTrials.gov Web site, September 30, 2008.
35. Safety and efficacy of dapagliflozin as monotherapy in subjects with type 2 diabetes (NCT00736879). ClinicalTrials.gov Web site, September 30, 2008.
36. An efficacy & safety study of BMS-512148 in combination with metformin extended release tablets (NCT00643851). ClinicalTrials.gov Web site, September 30, 2008.
37. Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients (NCT00660907). ClinicalTrials.gov Web site, September 30, 2008.
38. Efficacy and safety of dapagliflozin in combination with glimepiride (a sulphonylurea) in type 2 diabetes patients (NCT00680745). ClinicalTrials.gov Web site, September 30, 2008.
39. Efficacy and safety of dapagliflozin, added to therapy of patients with type 2 diabetes with inadequate glycemic control on insulin (NCT00673231). ClinicalTrials.gov Web site, September 30, 2008.
40. Renal mechanism of action/splay vs. TmG (MOA) (NCT00726505). ClinicalTrials.gov Web site, September 30, 2008.